Angiotensin converting enzyme and angiotensin converting enzyme inhibitors in dermatology: a narrative review

References

• Wong J, Patel RA, Kowey PR. The clinical use of angiotensin-converting enzyme inhibitors. Prog Cardiovasc Dis. 2004;47(2):116–130.
   Google Scholar
• Riordan JF. Angiotensin-I-converting enzyme and its relatives. Genome Biol. 2003;4(8):225.
   Google Scholar
• Nakai K, Syoh T, Hiramori K. Angiotensin-I converting enzyme. Nihon Rinsho. 1995;53(5):1232–1236.
   Google Scholar
• Crisan D, Carr J. Angiotensin I-converting enzyme: genotype and disease associations. J Mol Diagn. 2000;2(3):105–115.
   Google Scholar
• Khan S, Dar SA, Mandal RK, et al. Angiotensin-converting enzyme gene I/D polymorphism is associated with systemic lupus erythematosus susceptibility: an updated meta-analysis and trial sequential analysis. Front Physiol. 2018;9:1793.
   Google Scholar
• Almohideb M. Associations of angiotensin-converting enzyme gene insertion/deletion (ACE Gene I/D) polymorphism with vitiligo: an updated systematic review and meta-analysis. Cureus. 2020;12(5):e8046.
   Google Scholar
• Chang YC, Wu WM, Chen CH, et al. Association between the insertion/deletion polymorphism of the angiotensin I-converting enzyme gene and risk for psoriasis in a Chinese population in Taiwan. Br J Dermatol. 2007;156(4):642–645. DOI:10.1111/j.1365-2133.2006.07716.x.
   Google Scholar
• Lo Y, Lin LY, Tsai TF. Use of calcium channel blockers in dermatology: a narrative review. Expert Rev Clin Pharmacol. 2021;14(4):481–489.
   Google Scholar
• Baccino D, Merlo G, Cozzani E, et al. Cutaneous effects of antihypertensive drugs. G Ital Dermatol Venereol. 2020;155(2):202–211. DOI:10.23736/S0392-0488.19.06360-0.
   Google Scholar
• Ranugha PSS, Betkerur JB. Antihypertensives in dermatology Part II - cutaneous adverse reactions to antihypertensives. Indian J Dermatol Venereol Leprol. 2018;84(2):137–147. DOI:10.4103/ijdvl.IJDVL_992_16.
   Google Scholar
• Steckelings UM, Artuc M, Wollschläger T, et al. Angiotensin-converting enzyme inhibitors as inducers of adverse cutaneous reactions. Acta Derm Venereol. 2001;81(5):321–325. DOI:10.1080/000155501317140007.
   Google Scholar
• Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev. 2006;86(3):747–803.
   Google Scholar
• Steckelings UM, Czarnetzki BM. The renin-angiotensin- system in the skin. Evidence for its presence and possible functional implications. Exp Dermatol. 1995;4(6):329–334.
   Google Scholar
• Aleksiejczuk M, Gromotowicz-Poplawska A, and Marcinczyk N, et al. The expression of the renin-angiotensin-aldosterone system in the skin and its effects on skin physiology and pathophysiology. J Physiol Pharmacol. 2019;70(3). DOI:10.26402/jpp.2019.3.01.
   Google Scholar
• Silva IMS, Assersen KB, and Willadsen NN, et al., The role of the renin-angiotensin system in skin physiology and pathophysiology. Exp Dermatol. 2020;29(9): 891–901. DOI: 10.1111/exd.14159.
   Google Scholar
• Jones OM, Brading AF, Mortensen NJ. The physiology, pharmacology and therapeutic manipulation of the internal anal sphincter. Can J Gastroenterol. 2002;16(4):249–257.
   Google Scholar
• De Godoy MA, Rattan S. Autocrine regulation of internal anal sphincter tone by renin-angiotensin system: comparison with phasic smooth muscle. Am J Physiol Gastrointest Liver Physiol. 2005;289(6):G1164–1175.
   Google Scholar
• De Godoy MA, Rattan S. Angiotensin-converting enzyme and angiotensin II receptor subtype 1 inhibitors restitute hypertensive internal anal sphincter in the spontaneously hypertensive rats. J Pharmacol Exp Ther. 2006;318(2):725–734.
   Google Scholar
• Khaikin M, Bashankaev B, Sands D, et al. The effect of topical anal captopril on resting anal pressure in healthy volunteers: the first human pilot study. Tech Coloproctol. 2014;18(1):39–43. DOI:10.1007/s10151-013-0986-y.
   Google Scholar
• Ala S, Enayatifard R, Alvandipour M, et al. Comparison of captopril (0.5%) cream with diltiazem (2%) cream for chronic anal fissure: a prospective randomized double-blind two-centre clinical trial. Colorectal Dis. 2016;18(5):510–516. DOI:10.1111/codi.13147.
   Google Scholar
• Munavalli GG, Knutsen-Larson S, Lupo MP, et al. Oral angiotensin-converting enzyme inhibitors for treatment of delayed inflammatory reaction to dermal hyaluronic acid fillers following COVID-19 vaccination-a model for inhibition of angiotensin II-induced cutaneous inflammation. JAAD Case Rep. 2021;10:63–68. DOI:10.1016/j.jdcr.2021.02.018
   Google Scholar
• Zhao Q, Fang X, Pang Z, et al. COVID-19 and cutaneous manifestations: a systematic review. J Eur Acad Dermatol Venereol. 2020;34(11):2505–2510. DOI:10.1111/jdv.16778.
   Google Scholar
• Huang YW, Tsai TF. Skin manifestation and diagnosis of febrile diseases by COVID-19 and other ribonucleic acid viruses: the diagnostic clues. Dermatol Sinica. 2021;38(3):131–141.
   Google Scholar
• Munavalli GG, Guthridge R, Knutsen-Larson S, et al. COVID-19/SARS-CoV-2 virus spike protein-related delayed inflammatory reaction to hyaluronic acid dermal fillers: a challenging clinical conundrum in diagnosis and treatment. Arch Dermatol Res. 2022;314(1):1–15. DOI:10.1007/s00403-021-02190-6.
   Google Scholar
• Read GM. Verapamil and hair colour change. Lancet. 1991;338(8781):1520.
   Google Scholar
• Yale K, Juhasz M, Atanaskova Mesinkovska N. Medication-induced repigmentation of gray hair: a systematic review. Skin Appendage Disord. 2020;6(1):1–10.
   Google Scholar
• Itinteang T, Brasch HD, Tan ST, et al. Expression of components of the renin-angiotensin system in proliferating infantile haemangioma may account for the propranolol-induced accelerated involution. J Plast Reconstr Aesthet Surg. 2011;64(6):759–765.
   Google Scholar
• Tan ST, Itinteang T, Day DJ, et al. Treatment of infantile haemangioma with captopril. Br J Dermatol. 2012;167(3):619–624. DOI:10.1111/j.1365-2133.2012.11016.x.
   Google Scholar
• Christou EM, Wargon O. Effect of captopril on infantile haemangiomas: a retrospective case series. Australas J Dermatol. 2012;53(3):216–218.
   Google Scholar
• Zaher H, Rasheed H, El-Komy MM, et al. Propranolol versus captopril in the treatment of infantile hemangioma (IH): a randomized controlled trial. J Am Acad Dermatol. 2016;74(3):499–505. DOI:10.1016/j.jaad.2015.09.061.
   Google Scholar
• Sulzberger L, Baillie R, Itinteang T, et al. Serum levels of renin, angiotensin-converting enzyme and angiotensin II in patients treated by surgical excision, propranolol and captopril for problematic proliferating infantile haemangioma. J Plast Reconstr Aesthet Surg. 2016;69(3):381–386. DOI:10.1016/j.bjps.2015.10.020.
   Google Scholar
• Koh SP, Leadbitter P, Smithers F, et al. β-blocker therapy for infantile hemangioma. Expert Rev Clin Pharmacol. 2020;13(8):899–915. DOI:10.1080/17512433.2020.1788938.
   Google Scholar
• Steckelings UM, Henz BM, Wiehstutz S, et al. Differential expression of angiotensin receptors in human cutaneous wound healing. Br J Dermatol. 2005;153(5):887–893. DOI:10.1111/j.1365-2133.2005.06806.x.
   Google Scholar
• Yahata Y, Shirakata Y, Tokumaru S, et al. A novel function of angiotensin II in skin wound healing. Induction of fibroblast and keratinocyte migration by angiotensin II via heparin-binding epidermal growth factor (EGF)-like growth factor-mediated EGF receptor transactivation. J Biol Chem. 2006;281(19):13209–13216. DOI:10.1074/jbc.M509771200.
   Google Scholar
• Niazi F, Hooshyar SH, Hedayatyanfard K, et al. Detection of angiotensin II and AT1 receptor concentrations in keloid and hypertrophic scar. J Clin Aesthet Dermatol. 2018;11(10):36–39.
   Google Scholar
• Morihara K, Takai S, Takenaka H, et al. Cutaneous tissue angiotensin-converting enzyme may participate in pathologic scar formation in human skin. J Am Acad Dermatol. 2006;54(2):251–257. DOI:10.1016/j.jaad.2005.09.027.
   Google Scholar
• Stewart J, Glass Nd DA. Glass 2nd DA. Plasma angiotensin-converting enzyme levels in patients with keloids and/or hypertension. Wounds. 2018;30(7):E71–E72.
   Google Scholar
• Fang QQ, Wang XF, Zhao WY, et al. Angiotensin-converting enzyme inhibitor reduces scar formation by inhibiting both canonical and noncanonical TGF-β1 pathways. Sci Rep. 2018;8(1):3332. DOI:10.1038/s41598-018-21600-w.
   Google Scholar
• Chen J, Zhao S, Liu Y, et al. Effect of captopril on collagen metabolisms in keloid fibroblast cells. ANZ J Surg. 2016;86(12):1046–1051. DOI:10.1111/ans.12670.
   Google Scholar
• Safaee Ardekani G, Ebrahimi S, Amini M, et al. Topical captopril as a novel agent against hypertrophic scar formation in New Zealand white rabbit skin. Wounds. 2008;20(4):101–106.
   Google Scholar
• Kim DY, Han YS, Kim SR, et al. Effects of a topical angiotensin-converting enzyme inhibitor and a selective COX-2 inhibitor on the prevention of hypertrophic scarring in the skin of a rabbit ear. Wounds. 2012;24(12):356–364.
   Google Scholar
• Tan WQ, Fang QQ, Shen XZ, et al. Angiotensin-converting enzyme inhibitor works as a scar formation inhibitor by down-regulating smad and TGF-β-activated kinase 1 (TAK1) pathways in mice. Br J Pharmacol. 2018;175(22):4239–4252. DOI:10.1111/bph.14489.
   Google Scholar
• Zheng B, Fang -Q-Q, Wang X-F, et al. The effect of topical ramipril and losartan cream in inhibiting scar formation. Biomed Pharmacother. 2019;118:109394.
   Google Scholar
• Mohammadi AA, Parand A, Kardeh S, et al. Efficacy of topical enalapril in treatment of hypertrophic scars. World J Plast Surg. 2018;7(3):326–331. DOI:10.29252/wjps.7.3.326.
   Google Scholar
• Hedayatyanfard K, Ziai SA, Niazi F, et al. Losartan ointment relieves hypertrophic scars and keloid: a pilot study. Wound Repair Regen. 2018;26(4):340–343. DOI:10.1111/wrr.12648.
   Google Scholar
• Iannello S, Milazzo P, Bordonaro F, et al. Low-dose enalapril in the treatment of surgical cutaneous hypertrophic scar and keloid–two case reports and literature review. MedGenMed. 2006;8(4):60.
   Google Scholar
• Davis TA, Landauer MR, Mog SR, et al. Timing of captopril administration determines radiation protection or radiation sensitization in a murine model of total body irradiation. Exp Hematol. 2010;38(4):270–281. DOI:10.1016/j.exphem.2010.01.004.
   Google Scholar
• Chisi JE, Briscoe CV, Ezan E, et al. Captopril inhibits in vitro and in vivo the proliferation of primitive haematopoietic cells induced into cell cycle by cytotoxic drug administration or irradiation but has no effect on myeloid leukaemia cell proliferation. Brit J Haematol. 2000;109(3):563–570. DOI:10.1046/j.1365-2141.2000.02073.x.
   Google Scholar
• Islam A, Bolduc DL, Zhai M, et al. Captopril increases survival after whole-body ionizing irradiation but decreases survival when combined with skin-burn trauma in mice. Radiat Res. 2015;184(3):273–279. DOI:10.1667/RR14113.1.
   Google Scholar
• Medhora M, Gasperetti T, Schamerhorn A, et al. Wound trauma exacerbates acute, but not delayed, effects of radiation in rats: mitigation by lisinopril. Int J Mol Sci. 2020;21(11):3908. DOI:10.3390/ijms21113908.
   Google Scholar
• Sorour NE, Mustafa AI, Alhusseni NF, et al. Angiotensin-converting enzyme gene insertion/deletion polymorphism and family history in severe acne vulgaris. J Cosmet Dermatol. 2019;18(6):1992–1997. DOI:10.1111/jocd.12937.
   Google Scholar
• Namazi MR, Ashraf A, Handjani F, et al. Angiotensin converting enzyme activity in alopecia areata. Enzyme Res. 2014;2014:694148.
   Google Scholar
• Fahim S, Montazer F, Tohidinik HR, et al. Serum and tissue angiotensin-converting enzyme in patients with alopecia areata. Indian J Dermatol Venereol Leprol. 2019;85(3):295–299. DOI:10.4103/ijdvl.IJDVL_158_17.
   Google Scholar
• Koronellos N, Yapijakis C, Katoulis A, et al. Association study indicates combined effect of interleukin-10 and angiotensin-converting enzyme in basal cell carcinoma development. Arch Dermatol Res. 2021;313(5):373–380. DOI:10.1007/s00403-020-02113-x.
   Google Scholar
• Yapijakis C, Koronellos N, Spyridonidou S, et al. Association of angiotensin-converting enzyme gene insertion/deletion polymorphism with decreased risk for basal cell carcinoma. Arch Dermatol Res. 2013;305(4):333–339. DOI:10.1007/s00403-012-1312-7.
   Google Scholar
• Papaggelopoulos J, Angelopoulou A, Avgoustidis D, et al. Association of polymorphisms in the genes of angiotensinogen and angiotensin receptors with risk for basal cell carcinoma. Anticancer Res. 2019;39(10):5525–5530. DOI:10.21873/anticanres.13745.
   Google Scholar
• Rosenthal T, Gavras I. Angiotensin inhibition and malignancies: a review. J Hum Hypertens. 2009 Oct;23(10):623–635.
   Google Scholar
• Lindberg H, Nielsen D, Jensen BV, et al. Angiotensin converting enzyme inhibitors for cancer treatment? Acta Oncol. 2004;43(2):142–152.
   Google Scholar
• Drucker AM, Hollestein L, Na Y, et al. Association between antihypertensive medications and risk of skin cancer in people older than 65 years: a population-based study. CMAJ. 2021;193(15):E508–E516. DOI:10.1503/cmaj.201971.
   Google Scholar
• Gandini S, Palli D, Spadola G, et al. Anti-hypertensive drugs and skin cancer risk: a review of the literature and meta-analysis. Crit Rev Oncol Hematol. 2018;122:1–9. DOI:10.1016/j.critrevonc.2017.12.003
   Google Scholar
• Christian JB, Lapane KL, Hume AL, et al. VATTC trial. Association of ACE inhibitors and angiotensin receptor blockers with keratinocyte cancer prevention in the randomized VATTC trial.J Natl Cancer Inst. 2008 [Sep 3];100(17):1223–1232. DOI:10.1093/jnci/djn262.
   Google Scholar
• Tang H, Fu S, Zhai S, et al. Use of antihypertensive drugs and risk of keratinocyte carcinoma: a meta-analysis of observational studies. Pharmacoepidemiol Drug Saf. 2018 Mar;27(3):279–288.
   Google Scholar
• Hu B, Guo H, Zhou P, et al. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19(3):141–154. DOI:10.1038/s41579-020-00459-7.
   Google Scholar
• Ni W, Yang X, Yang D, et al. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Crit Care. 2020;24(1):422. DOI:10.1186/s13054-020-03120-0.
   Google Scholar
• Zamorano Cuervo N, Grandvaux N. ACE2: evidence of role as entry receptor for SARS-CoV-2 and implications in comorbidities. Elife. 2020;9:e61390.
   Google Scholar
• Bourgonje AR, Abdulle AE, Timens W, et al. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). J Pathol. 2020;251(3):228–248.
   Google Scholar
• Singh H, Kaur H, Singh K, et al. Cutaneous manifestations of COVID-19: a systematic review. Adv Wound Care (New Rochelle). 2021;10(2):51–80.
   Google Scholar
• Iranmanesh B, Khalili M, Amiri R, et al. Oral manifestations of COVID-19 disease: a review article. Dermatol Ther. 2021;34(1):e14578.
   Google Scholar
• García‐Gil MF, Monte‐Serrano J, García García M, et al. Absence of SARS-CoV-2 RNA detection in tissue samples of COVID-19-related cutaneous lesions analyzed by real-time RT-PCR. J Eur Acad Dermatol Venereol. 2021;35(5):e318–e321.
   Google Scholar
• Hamouda Elgarhy L. Could patients taking isotretinoin therapy be immune against SARS-CoV-2? Dermatol Ther. 2020;33(4):e13573.
   Google Scholar
• Sinha S, Cheng K, Schäffer AA, et al. In vitro and in vivo identification of clinically approved drugs that modify ACE2 expression. Mol Syst Biol. 2020;16(7):e9628. DOI:10.15252/msb.20209628.
   Google Scholar
• Huskić J, Mulabegović N, Alendar F, et al. Serum and tissue angiotensin converting enzyme in patients with psoriasis. Coll Antropol. 2008;32(4):1215–1219.
   Google Scholar
• Abdollahimajd F, Niknezhad N, Haghighatkhah HR, et al. Angiotensin-converting enzyme and subclinical atherosclerosis in psoriasis: is there any association? A case-control study. J Am Acad Dermatol. 2020;82(4):980–981.e1. DOI:10.1016/j.jaad.2018.08.003.
   Google Scholar
• Yang K, Zhang F, Li F, et al. Angiotensin-converting enzyme insertion/deletion polymorphism and susceptibility to psoriasis in a Chinese population. J Renin Angiotensin Aldosterone Syst. 2014;15(1):39–43. DOI:10.1177/1470320313494433.
   Google Scholar
• Ramezani M, Zavattaro E, Sadeghi M. Angiotensin-converting enzyme gene insertion/deletion polymorphism and susceptibility to psoriasis: a systematic review and meta-analysis. BMC Med Genet. 2020;21(1):8.
   Google Scholar
• Shahidi-Dadras M, Tabary M, Robati RM, et al. Psoriasis and risk of the COVID-19: is there a role for angiotensin converting enzyme (ACE)? J Dermatolog Treat. 2020;30:1–2.
   Google Scholar
• Tembhre MK, Parihar AS, Sharma VK, et al. Enhanced expression of angiotensin-converting enzyme 2 in psoriatic skin and its upregulation in keratinocytes by interferon-γ: implication of inflammatory milieu in skin tropism of SARS-CoV-2. Br J Dermatol. 2021;184(3):577–579. DOI:10.1111/bjd.19670.
   Google Scholar
• Response to Tembhre. Gehlhausen JR, Ko CJ, Damsky W, et al. Enhanced expression of angiotensin-converting enzyme 2 in psoriatic skin and its upregulation in keratinocytes by interferon-γ: implication of inflammatory milieu in skin tropism of SARS-CoV-2. Br J Dermatol. 2021;184(5):984.
   Google Scholar
• Schälter F, Dürholz K, Bucci L, et al. Does methotrexate influence COVID-19 infection? Case series and mechanistic data. Arthritis Res Ther. 2021 [Jun 10];23(1):166. DOI:10.1186/s13075-021-02464-4.
   Google Scholar
• Krueger JG, Murrell DF, Garcet S, et al. Secukinumab lowers expression of ACE2 in affected skin of patients with psoriasis. J Allergy Clin Immunol. 2021 Mar;147(3):1107–1109.e2. DOI:10.1016/j.jaci.2020.09.021.
   Google Scholar
• Mahil SK, Dand N, Mason KJ, et al. Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study. J Allergy Clin Immunol. 2021 Jan;147(1):60–71. DOI:10.1016/j.jaci.2020.10.007.
   Google Scholar
• Lieberman J. Elevation of serum angiotensin-converting-enzyme (ACE) level in sarcoidosis. Am J Med. 1975;59(3):365–372.
   Google Scholar
• Song GG, Kim JH, Lee YH. Associations between the angiotensin-converting enzyme insertion/deletion polymorphism and susceptibility to sarcoidosis: a meta-analysis. J Renin Angiotensin Aldosterone Syst. 2015;16(1):219–226.
   Google Scholar
• Tahir M, Sharma SK, Ashraf S, et al. Angiotensin converting enzyme genotype affects development and course of sarcoidosis in Asian Indians. Sarcoidosis Vasc Diffuse Lung Dis. 2007;24(2):106–112.
   Google Scholar
• Kaura V, Kaura SH, Kaura CS. ACE inhibitor in the treatment of cutaneous and lymphatic sarcoidosis. Am J Clin Dermatol. 2007;8(3):183–186.
   Google Scholar
• Kaura V, Kaura NV, Kaura BN, et al. Angiotensin-converting enzyme inhibitors in the treatment of sarcoidosis and association with ACE gene polymorphism: case series. Indian J Chest Dis Allied Sci. 2007;55(2):105–107.
   Google Scholar
• Mizuno K, Okamoto H, Horio T. Inhibitory influences of xanthine oxidase inhibitor and angiotensin I-converting enzyme inhibitor on multinucleated giant cell formation from monocytes by downregulation of adhesion molecules and purinergic receptors. Br J Dermatol. 2004 Feb;150(2):205–210.
   Google Scholar
• Pfeffer MA, Pfeffer JM, Steinberg C, et al. Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril. Circulation. 1985 Aug;72(2):406–412.
   Google Scholar
• Marzano AV, Vezzoli P, Crosti C. Drug-induced lupus: an update on its dermatologic aspects. Lupus. 2009 Oct;18(11):935–940.
   Google Scholar
• Dalle Vedove C, Simon JC, Girolomoni G. Drug-induced lupus erythematosus with emphasis on skin manifestations and the role of anti-TNFα agents. J Dtsch Dermatol Ges. 2012 Dec;10(12):889–897.
   Google Scholar
• Hammad A, Yahia S, Laimon W, et al. Angiotensin-converting enzyme insertion/deletion gene polymorphism in Egyptian children with systemic lupus erythematosus: a possible relation to proliferative nephritis. Lupus. 2017;26(7):762–767. DOI:10.1177/0961203316682096.
   Google Scholar
• Huang AF, Li H, Ke L, et al. Association of angiotensin-converting enzyme insertion/deletion polymorphism with susceptibility to systemic lupus erythematosus: a meta-analysis. Int J Rheum Dis. 2018;21(2):447–457. DOI:10.1111/1756-185X.13236.
   Google Scholar
• Anders HJ, Saxena R, Zhao MH, et al. Lupus nephritis. Nat Rev Dis Primers. 2020;6(1):7. DOI:10.1038/s41572-019-0141-9.
   Google Scholar
• Patwardhan M, Pradhan V, Taylor LH, et al. The angiotensin-converting enzyme gene insertion/deletion polymorphism in Indian patients with vitiligo: a case-control study and meta-analysis. Br J Dermatol. 2013;168(6):1195–1204. DOI:10.1111/bjd.12177.
   Google Scholar
• Tippisetty S, Ishaq M, Komaravalli PL, et al. Angiotensin converting enzyme (ACE) gene polymorphism in vitiligo: protective and predisposing effects of genotypes in disease susceptibility and progression. Eur J Dermatol. 2011;21(2):173–177. DOI:10.1684/ejd.2011.1279.
   Google Scholar
• Kataria V, Wang H, Wald JW, et al. Lisinopril-induced alopecia: a case report. J Pharm Pract. 2017;30(5):562–566. DOI:10.1177/0897190016652554.
   Google Scholar
• Motel PJ. Captopril and alopecia: a case report and review of known cutaneous reactions in captopril use. J Am Acad Dermatol. 1990;23(1):124–125.
   Google Scholar
• Ahmad S. Enalapril and reversible alopecia. Arch Intern Med. 1991;151(2):404.
   Google Scholar
• Vleeming W, van Amsterdam JG, Stricker BH, et al. ACE inhibitor-induced angioedema. Incidence, prevention and management. Drug Saf. 1998;18(3):171–188. DOI:10.2165/00002018-199818030-00003.
   Google Scholar
• Makani H, Messerli FH, Romero J, et al. Meta-analysis of randomized trials of angioedema as an adverse event of renin-angiotensin system inhibitors. Am J Cardiol. 2012;110(3):383–391. DOI:10.1016/j.amjcard.2012.03.034.
   Google Scholar
• Shionoiri H, Takasaki I, Hirawa N, et al. A case report of angioedema during long-term (66 months) angiotensin converting enzyme inhibition therapy with enalapril. Jpn Circ J. 1996;60(3):166–170. DOI:10.1253/jcj.60.166.
   Google Scholar
• Puppin D Jr, Rybojad M, de la Chapelle C, et al. Kaposi’s sarcoma associated with captopril. Lancet. 1990;336(8725):1251–1252. DOI:10.1016/0140-6736(90)92866-G.
   Google Scholar
• Larbre JP, Nicolas JF, Collet P, et al. Kaposi’s sarcoma in a patient with rheumatoid arthritis possible responsibility of captopril in the development of lesions. J Rheumatol. 1991;18(3):476–477.
   Google Scholar
• Bilen N, Bayramgürler D, Aydeniz B, et al. Possible causal role of lisinopril in a case of Kaposi’s sarcoma. Br J Dermatol. 2002;147(5):1042–1044. DOI:10.1046/j.1365-2133.2002.507116.x.
   Google Scholar
• Ruocco E, Ruocco V, Tornesello ML, et al. Kaposi’s sarcoma: etiology and pathogenesis, inducing factors, causal associations, and treatments: facts and controversies. Clin Dermatol. 2013;31(4):413–422. DOI:10.1016/j.clindermatol.2013.01.008.
   Google Scholar
• Ong CS, Cook N, Lee S. Drug-related pemphigus and angiotensin converting enzyme inhibitors. Australas J Dermatol. 2000;41(4):242–246.
   Google Scholar
• Palleria C, Bennardo L, Dastoli S, et al. Angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers induced pemphigus: a case series and literature review. Dermatol Ther. 2019;32(1):e12748. DOI:10.1111/dth.12748.
   Google Scholar
• Ghaedi F, Etesami I, Aryanian Z, et al. Drug-induced pemphigus: a systematic review of 170 patients. Int Immunopharmacol. 2021;92:107299.
   Google Scholar
• Cozzani E, Rosa GM, Drosera M, et al. ACE inhibitors can induce circulating antibodies directed to antigens of the superficial epidermal cells. Arch Dermatol Res. 2011;303(5):327–332. DOI:10.1007/s00403-010-1060-5.
   Google Scholar
• Baroni A, Buommino E, Ruocco E, et al. Captopril modulates acetylcholinesterase in human keratinocytes. Arch Dermatol Res. 2011;303(7):491–497. DOI:10.1007/s00403-011-1124-1.
   Google Scholar
• Kalińska-Bienias A, Rogoziński TT, Woźniak K, et al. Can pemphigoid be provoked by lisinopril? Br J Dermatol. 2006;155(4):854–855. DOI:10.1111/j.1365-2133.2006.07453.x.
   Google Scholar
• Ballout RA, Musharrafieh U, Khattar J. Lisinopril-associated bullous pemphigoid in an elderly woman: a case report of a rare adverse drug reaction. Br J Clin Pharmacol. 2018;84(11):2678–2682.
   Google Scholar
• Ben Salem C, Chenguel L, Ghariani N, et al. Captopril-induced lichen planus pemphigoides. Pharmacoepidemiol Drug Saf. 2008;17(7):722–724. DOI:10.1002/pds.1618.
   Google Scholar
• Onprasert W, Chanprapaph K. Lichen planus pemphigoides induced by enalapril: a case report and a review of literature. Case Rep Dermatol. 2017;9(3):217–224.
   Google Scholar
• Azzouz B, Morel A, Kanagaratnam L, et al. Psoriasis after exposure to angiotensin-converting enzyme inhibitors: French pharmacovigilance data and review of the literature. Drug Saf. 2019;42(12):1507–1513. DOI:10.1007/s40264-019-00865-8.
   Google Scholar
• Brauchli YB, Jick SS, Curtin F, et al. Association between beta-blockers, other antihypertensive drugs and psoriasis: population-based case–control study. Br J Dermatol. 2008;158(6):1299–1307. DOI:10.1111/j.1365-2133.2008.08563.x.
   Google Scholar
• Wu S, Han J, Li W-Q, et al. Hypertension, antihypertensive medication use, and risk of psoriasis. JAMA Dermatol. 2014;150(9):957–963. DOI:10.1001/jamadermatol.2013.9957.
   Google Scholar
• Song G, Kim JY, Yoon HY, et al. A systematic review and meta-analysis of angiotensin-converting enzyme inhibitor use and psoriasis incidence. Sci Rep. 2021;11(1):10037. DOI:10.1038/s41598-021-89490-z.
   Google Scholar
• Wolf R, Machtey I, Feverman EJ, et al. The kallikrein-kinin pathway in psoriasis. Preliminary observations. Biomedicine. 1981;35(3): 77–78
   Google Scholar
• Terenzi R, Manetti M, Rosa I, et al. Angiotensin II type 2 receptor (AT2R) as a novel modulator of inflammation in rheumatoid arthritis synovium. Sci Rep. 2017;7(1):13293. DOI:10.1038/s41598-017-13746-w.
   Google Scholar
• Tanhapour M, Falahi B, and Vaisi-Raygani A, et al. Angiotensin-converting enzyme insertion/deletion (rs106180) and angiotensin type 1 receptor A1166 C (rs106165) genotypes and psoriasis: correlation with cellular immunity, lipid profile, and oxidative stress markers. J Cell Biochem. 2018. DOI:10.1002/jcb.27569.
   Google Scholar
• Alrashidi A, Rhodes LE, Sharif JCH, et al. Systemic drug photosensitivity—Culprits, impact and investigation in 122 patients. Photodermatol Photoimmunol Photomed. 2020;36(6):441–451. DOI:10.1111/phpp.12583.
   Google Scholar
• Abidi N, Foering K, Sahu J. Acquired brachial cutaneous dyschromatosis in a 60-year-old male: a case report and review of the literature. Case reports in Dermatological Medicine. 2014;2014:452720.
   Google Scholar
• Vena GA, Cassano N, Coco V, et al. Eczematous reactions due to angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers. Immunopharmacol Immunotoxicol. 2013;35(3):447–450. DOI:10.3109/08923973.2013.797992.
   Google Scholar
• Monastirli A, Pasmatzi E, Badavanis G, et al. Gestational Pityriasis rosea: suggestions for approaching affected pregnant women. Acta Dermatovenerol Croat. 2016;24(4):312–313.
   Google Scholar
• Vaduganathan M, Vardeny O, Michel T, et al. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N Engl J Med. 2020;382(17):1653–1659. DOI:10.1056/NEJMsr2005760.
   Google Scholar
• Mancia G, Rea F, Ludergnani M, et al. Renin-angiotensin-aldosterone system blockers and the risk of Covid-19. N Engl J Med. 2020;382(25):2431–2440. DOI:10.1056/NEJMoa2006923.
   Google Scholar
• Fosbøl EL, Butt JH, Østergaard L, et al. Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality. JAMA. 2020;324(2):168–177. DOI:10.1001/jama.2020.11301.
   Google Scholar